Skip to main content
SpringerLink
Log in

Ocular Myasthenia

  • Chapter
Myasthenia Gravis and Related Disorders

Part of the book series: Current Clinical Neurology ((CCNEU))

Abstract

Myasthenia gravis (MG) is a generalized disorder that often manifests initially as focal weakness. The most common focal presentation is ocular. Ocular muscle weakness at the onset of MG is present in 85–90% of patients, but the percentage of those without clinical evidence of coexisting bulbar or limb weakness (i.e., pure ocular myasthenia) varies from 15 to 59% in different series(1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Daroff RB. Ocular myasthenia: diagnosis and therapy. In: Glaser JS, ed. Neuro-ophthalmology, vol X. St. Louis, CV Mosby, 1980, pp. 62–71.

    Google Scholar 

  2. Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann NY Acad Sci 1987; 505: 472–499.

    Article  PubMed  CAS  Google Scholar 

  3. Porter JD, Baker RS. Muscle of a different ‘color’: the unusual properties of the extraocular muscles may predispose or protect them in neurogenic and myogenic disease. Neurology 1996; 46: 30–37.

    Article  PubMed  CAS  Google Scholar 

  4. Kaminski HJ, Ruff RL. Ocular muscle involvement by myasthenia gravis. Ann Ne urol 1997; 41: 419–420.

    Article  CAS  Google Scholar 

  5. Kaminski HJ. Acetylcholine receptor epitopes in ocular myasthenia. Ann NY Acad Sci 1998; 841: 309–319.

    Article  PubMed  CAS  Google Scholar 

  6. Niemann CU, Krag TOB, Khurana TS. Identification of genes that are differentially expressed in extraocular and limb muscle. J Neurol Sci 2000; 179: 76–84.

    Article  PubMed  CAS  Google Scholar 

  7. Ubogu EE, Kaminski HJ. The preferential involvement of extraocular muscles by myasthenia gravis. Neuroophthalmol 2001; 25: 219–228.

    Article  Google Scholar 

  8. Horton RM, Manfredi AA, Conti-Tronconi BM. The émbryonic’ gamma subunit of the nicotine acetylcholine receptor is expressed in adult extraocular muscle. Neurology 1993; 43: 983–986.

    Article  PubMed  CAS  Google Scholar 

  9. Kaminski HJ, Kusner LL, Nash KV, Ruff RL. The gamma subunit of the acetylcholine receptor is not expressed in the levator palpebrae superioris. Neurology 1995; 45: 516–518.

    Article  PubMed  CAS  Google Scholar 

  10. Marino M, Barbesino G, Pinchera A, et al. Increased frequency of euthyroid ophthalmopathy in patients with Graves’ disease associated with myasthenia gravis. Thyroid 2000; 10: 799–802.

    Article  PubMed  CAS  Google Scholar 

  11. Glaser JS, Siatkowski. Infranuclear disorders of eye movement. In: Glaser JS, ed. Neuroophthalmology, 3rd ed. Philadelphia, Lippincott Williams and Wilkins, 1999, pp. 405–459.

    Google Scholar 

  12. Cooper J, Kruger P, Panariello G. The pathognomonic pattern of accommodative fatigue in myasthenia gravis. BinoculVis Strabismus Q 1988; 3: 141–148.

    Google Scholar 

  13. Kuncl RW, Hoffman PN. Myopathies and disorders of neuromuscular transmission. In: Miller NR, Newman NJ, eds. aWlsh and Hoyt’s Clinical Neuro-Ophthalmology, 5th ed., vol 1. Baltimore, Williams and Wilkins, 1998, pp. 1351–1431.

    Google Scholar 

  14. Loewenfeld IE. The Pupil: Anatomy, Physiology, and Clinical Applications. Boston, Butterworth Heinemann, 1999, pp. 1364–1366.

    Google Scholar 

  15. Thompson HS, Miller NR. Disorders of pupillary function, accommodation, and lacrimation. In: Miller NR, Newman NJ, eds. aWlsh and Hoyt’s Clinical Neuroopthalmology, 5th ed., vol 1. Baltimore, Williams and Wilkins, 1998, pp. 961–999.

    Google Scholar 

  16. Barton JJS. Ocular aspects of myasthenia gravis. Semin Neurol 2000; 20: 7–20.

    Article  PubMed  CAS  Google Scholar 

  17. Valmaggia C, Gottlob I. Cocaine abuse, generalized myasthenia, complete external ophthalmoplegia, and pseudotonic pupil. Strabismus 2001; 9: 9–12.

    Article  PubMed  CAS  Google Scholar 

  18. Yee RD, Cogan DG, Zee DS, Baloh RW, Honrubia V. Rapid eye movements in myasthenia gravis. II. Electro-oculographic analysis. Arch Ophthalmol 1976; 94: 1465–1472.

    Article  PubMed  CAS  Google Scholar 

  19. Ragge ML, Hoyt WF. Midbrain myasthenia: fatigable ptosis, l‘id twitch’ sign, and ophthalmoparesis from a dorsal midbrain glioma. Neurology 1992; 42: 917–919.

    Article  PubMed  CAS  Google Scholar 

  20. Kao Y-F, Lan M-Y, Chou M-S, Chen W-H. Intracranial fatigable ptosis. J Neuroophthalmol 1999; 19: 257–259.

    Article  PubMed  CAS  Google Scholar 

  21. Averbuch-Heller L, Poonyathalang A, von Maydell RD, Remler BF. Hering’s law for eyelids: still valid. Neurology 1996; 45: 1781–1783.

    Article  Google Scholar 

  22. McConville J, Hoch W, Newsom-Davis J, Vincent A. Antibodies to the muscle specific kinase, MuSK, in generalised and ocular myasthenia gravis seronegative for acetylcholine receptor antibodies. J Neurol Sci 2001; 187 (Suppl 1):S 122–S123.

    Google Scholar 

  23. Oosterhuis HJ. The ocular signs and symptoms of myasthenia gravis. Doc Ophthalmol 1982; 52: 363–378.

    Article  PubMed  CAS  Google Scholar 

  24. Sanders, DB. Electrophysiological and pharmacological tests in neuromuscular junction disorders. In: Lisak RP, ed. Handbook of Myasthenia Gravis andMyasthenic Syndromes. New York, Marcel Dekker, 1994, pp. 103–148.

    Google Scholar 

  25. Binnie CD, Cooper R, Fowler CJ, Mauguieè F, Prior PF. EMG, nerve conduction and evoked potentials. In: Osselton JW, ed. Clinical Neurophysiology. Boston, Butter-worth Heinemann, 1995, pp. 201–204.

    Google Scholar 

  26. Padua L, Stalberg E, LoMonaco M, et al. SFEMG in ocular myasthenia gravis diagnosis. Clin Neurophysiol 2000; 111: 1203–1207.

    Article  PubMed  CAS  Google Scholar 

  27. Valls-Canals J, Montero J, Pradas J. Stimulated single fiber EMG of the frontalis muscle in the diagnosis of ocular myasthenia. Muscle Nerve 2000; 23: 779–783.

    Article  PubMed  CAS  Google Scholar 

  28. Daroff RB. The office Tensilon test for ocular myasthenia gravis. Arch Neurol 1986; 43: 843–844.

    Article  PubMed  CAS  Google Scholar 

  29. Seybold ME. The office Tensilon test for ocular myasthenia gravis. Arch Neurol 1986; 43: 842–843.

    Article  PubMed  CAS  Google Scholar 

  30. Barton JJS. Quantitative ocular tests for myasthenia gravis: a comparative review with detection theory analysis. J Neurol Sci 1998; 155: 104–114.

    Article  PubMed  CAS  Google Scholar 

  31. Yang Q, Wei M, Sun F, et al. Open-loop and closed-loop optokinetic nystagmus (OKN) in myasthenia gravis and nonmyasthenic subjects. Exp Neurol 2000; 166: 166–172.

    Article  PubMed  CAS  Google Scholar 

  32. Toth L, Toth A, Dioszeghy P, Repassy G. Electronystagmographic analysis of opto-kinetic nystagmus for the evaluation of ocular symptoms in myasthenia gravis. Acta Otolaryngol 1999; 119: 629–632.

    Article  PubMed  CAS  Google Scholar 

  33. Oh, SJ, Cho HK. Edrophonium responsiveness not necessarily diagnostic of myasthenia gravis. Muscle Nerve 1990; 13: 187–191.

    Article  PubMed  CAS  Google Scholar 

  34. Dirr LY, Troost BT. A false positive edrophonium test in a patient with a brain stem glioma. Neurology 1989; 39: 865–867.

    Article  PubMed  CAS  Google Scholar 

  35. Moorthy G, Behrens MM, Drachman DB, et al. Ocular pseudo-myasthenia or ocular myasthenia “plus”: a warning to clinicians. Neurology 1989; 39: 1150–1154.

    Article  PubMed  CAS  Google Scholar 

  36. Schmidt D. Signs in ocular myasthenia and pseudomyasthenia. Differential diagnostic criteria. Neuroophthalmology 1995; 15: 21–58.

    Article  Google Scholar 

  37. Kupersmith MJ, Latkany R, Straga J. Ocular myasthenia gravis: steroids, edrophonium dose, thymoma, and generalization. Neuroophthalmology 2001; 25: 39.

    Google Scholar 

  38. Ing EB, Ing SY, Ing T, Ramocki JA. The complication rate of edrophonium testing for suspected myasthenia gravis. Can J Ophthalmol 2000; 35: 141–145.

    PubMed  CAS  Google Scholar 

  39. Okun MS, Charriez CM, Bhatti MT, Watson RT, Swift T. Tensilon and the diagnosis of myasthenia gravis: are we using the Tensilon test too much? Neurologist 2001; 7: 295–299.

    Article  PubMed  CAS  Google Scholar 

  40. Odel JG, Winterkorn JM, Behrens MM. The sleep test for myasthenia gravis. A safe alternative to Tensilon. J Clin Neuroophthalmol 1991; 11: 288–292.

    PubMed  CAS  Google Scholar 

  41. Golnick KC, Pena R, Lee AG, Eggenberger ER. An ice test for the diagnosis of myasthenia gravis. Ophthalmology 1999; 106: 1282–1286.

    Article  Google Scholar 

  42. Larner AJ, Thomas DJ. Can myasthenia gravis be diagnosed with the i‘ce pack test’? A cautionary note. Postgrad Med J 2000; 76: 162–163.

    Article  PubMed  CAS  Google Scholar 

  43. Ellis FD, Hoyt CS, Ellis FJ, Jeffery AR, Sondhi N. Extraocular muscle responses to orbital cooling (ice test) for ocular myasthenia gravis diagnosis. J AAPOS 2000; 4: 271–281.

    Article  PubMed  CAS  Google Scholar 

  44. Jacobson DM. The i‘ce pack test’ for diagnosing myasthenia gravis. Ophthalmology 2000; 4: 622–623.

    Article  Google Scholar 

  45. Movaghar M, Slavin ML. Effect of local heat versus ice on blepharoptosis resulting from ocular myasthenia. Ophthalmology 2000; 107: 2209–2214.

    Article  PubMed  CAS  Google Scholar 

  46. Kubis KC, Denesh-Meyer HV, Savino PJ, Sergott RC. The ice test versus the rest test in myasthenia gravis. Ophthalmology 2000; 107: 1995–1998.

    Article  PubMed  CAS  Google Scholar 

  47. Bever CT Jr, Aquino AV, Penn AS, Loveless RA, Rowland LP. Prognosis of ocular myasthenia. Neurology 1980; 30: 387.

    Google Scholar 

  48. Bever CT, Aquino AV, Penn AS, Lovelace RE, Rowland LP. Prognosis of ocular myasthenia. Ann Neurol 1983; 14: 515–519.

    Article  Google Scholar 

  49. Weinberg DH, Rizzo JF, Hayes MT, Kneeland MD, Kelly JJ. Ocular myasthenia gravis: predictive value of single-fiber electromyography. Muscle Nerve 1999; 22: 1222–1227.

    Article  PubMed  CAS  Google Scholar 

  50. Mullaney P, Vajsar J, Smith R, Buncic JR. The natural history and ophthalmic involvement in childhood myasthenia gravis at The Hospital for Sick Children. Ophthalmology 2000; 107: 504–510.

    Article  PubMed  CAS  Google Scholar 

  51. Weizer JS, Lee AG, Coats DK. Myasthenia gravis with ocular involvement in older patients. Can J Ophthalmol 2001; 36: 26–33.

    PubMed  CAS  Google Scholar 

  52. Drachman DB. Management of ocular myasthenia gravis. In: Tusa RJ, Newman SA, eds. Neuroophthalmological Disorders, Diagnostic Wokr- Up and Management. New York, Marcel Dekker, 1995, pp. 265–275.

    Google Scholar 

  53. Kupersmith MJ, Moster M, Bhiyan S, Warren F, Weinberg H. Beneficial effects of corticosteroids on ocular myasthenia gravis. Arch Neurol 1996; 53: 802–804.

    Article  PubMed  CAS  Google Scholar 

  54. Sommer N, Sigg B, Melms A, Weller M, et al. Ocular myasthenia gravis: response to long term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 1997; 62: 156–162.

    Article  PubMed  CAS  Google Scholar 

  55. Agius MA. Treatment of ocular myasthenia with corticosteroids. Arch Neurol 2000; 57: 750–751.

    Article  PubMed  CAS  Google Scholar 

  56. Kaminski HJ, Daroff RB. Treatment of ocular myasthenia. Arch Neurol 2000; 57: 752–753.

    Article  PubMed  CAS  Google Scholar 

  57. Lloyd ME, Spector TD, Howard R. Osteoporosis in neurological disorders. J Neurol Neurosurg Psychiatry 2000; 68: 543–549.

    Article  PubMed  CAS  Google Scholar 

  58. Smith GDP, Stevens DL, Fuller GN. Myasthenia gravis, corticosteroids and osteoporosis prophylaxis. J Neurol 2001; 248: 151.

    Article  PubMed  CAS  Google Scholar 

  59. Beekman R, Kuks JB, Oosterhuis HJ. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients. J Neurol 1997; 244: 112–118.

    Article  PubMed  CAS  Google Scholar 

  60. Newsom-Davis J. Disorders of the neuromuscular junction. In: Scolding N, ed. Contemporary Treatments in Neurology. Oxford, Butterworth Heinemann, 2001, pp. 158–169.

    Google Scholar 

  61. Evoli A, Batocchi AP, Minisci C, Di Schino C, Tonali P. Therapeutic options in ocular myasthenia gravis. Neuromuscul Disord 2001; 11: 208–216.

    Article  PubMed  CAS  Google Scholar 

  62. Sanders DB, Howard JF Jr. Disorders of neuromuscular transmission. In: Bradley WG, Daroff RB, Fenichel GM, Marsden CD, eds. Neurology in Clinical Practice:The Neurological Disorders, 3rd ed. Boston, Butterworth Heinemann, 2000, pp. 2167–2185.

    Google Scholar 

  63. Bentley CR, Dawson E, Lee JP. Active management in patients with ocular manifestations of myasthenia gravis. Eye 2001; 15: 18–22.

    Article  PubMed  CAS  Google Scholar 

  64. Bradley EA, Bartley GB, Chapman KL, Waller RR. Surgical correction of blepharoptosis in patients with myasthenia gravis. Ophthalmol Plast Reconstr Surg 2001; 17: 103–110.

    Article  CAS  Google Scholar 

  65. Sergott RC. Ocular myasthenia. In: Lisak RP, ed. Handbook of Myasthenia Gravis andMyasthenic Syndromes. New York, Marcel Dekker, 1994, pp. 21–31.

    Google Scholar 

  66. Sanders DB, Massey EW, Buckley EG. Botulinum toxin for blepharospasm: single-fiber EMG studies. Neurology 1986; 36: 545–547.

    Article  PubMed  CAS  Google Scholar 

  67. Lange DJ, Rubin M, Greene PE, et al. Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle Nerve 1991; 14: 672–675.

    Article  PubMed  CAS  Google Scholar 

  68. Ferguson FR, Hutchinson EC, Liversedge LA. Myasthenia gravis: results of medical management. Lancet 1955; 2: 636–639.

    Article  Google Scholar 

  69. Osserman KE. Myasthenia gravis. New York, Grune and Stratton, 1955.

    Google Scholar 

  70. Perlo VP, Poskanzer DC, Schwab RS, Viets HR, Osserman KE, Genkins G. Myasthenia gravis: evaluation of treatment in 1,355 patients. Neurology 1966; 16:431– 439.

    Google Scholar 

  71. Simpson JF, Westerberg MR, Magee KR. Myasthenia gravis: an analysis of 295 cases. Acta Neurol Scand 1966; 42 (Suppl): 1–27.

    PubMed  Google Scholar 

Download references

Authors
  1. Robert B. Daroff
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Departments of Neurology and Neurosciences, University Hospitals of Cleveland, Louis Stokes Cleveland Veterans Affairs Medical Center, Case Western Reserve University, Cleveland, OH, USA

    Henry J. Kaminski MD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Daroff, R.B. (2003). Ocular Myasthenia. In: Kaminski, H.J. (eds) Myasthenia Gravis and Related Disorders. Current Clinical Neurology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-341-5_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-341-5_5

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-5942-6

  • Online ISBN: 978-1-59259-341-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation